OrbiMed launches $222 million fund in Israel life sciences

Tuesday, April 24, 2012 12:18 PM

OrbiMed, a global investment management firm focused on the healthcare sector, has closed its first investment fund dedicated to life sciences venture capital opportunities based in Israel. The Fund, OrbiMed Israel Partners Limited Partnership, includes an anchor investment provided by the government of Israel, which also provided special economic terms through the initial tender process for the Fund.

OrbiMed Israel Partners is led by three full-time Israel-based partners, Dr. Nissim Darvish, Anat Naschitz and Erez Chimovits.

 OrbiMed Israel builds on OrbiMed's longstanding investment interest in Israel, which has led to multiple investments over the past decade, including early-stage investments in Given Imaging and SuperDimension (acquired by Covidien).

Dr. Darvish, senior managing director at OrbiMed Israel, said the new fund invests in biotechnology, pharmaceutical, medical device and diagnostics companies at varying stages of maturity, from seed stage through growth equity. It already has made two investments: Keystone Heart, developing an embolic protection device for interventional cardiology procedures, and Otic Pharma, developing foam formulations for ear medication.

OrbiMed is dedicated exclusively to the life sciences sector, with approximately $6 billion in assets under management. It invests across pharmaceutical, biotechnology and medical device companies worldwide, with offices in New York City, Tel Aviv, San Francisco, Shanghai and Mumbai.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs